DOCSLIB.ORG

25 Amino Acids 26 Chemicals 27 – 35 Nutritionals 36 – 52

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
25 Amino Acids 26 Chemicals 27 – 35 Nutritionals 36 – 52 PRODUCT LIST PRODUCT CATEGORY PAGE NO. Pharmaceuticals (API) 2 – 10 Intermediates 11 – 25 Amino Acids 26 Chemicals 27 – 35 Nutritionals 36 – 52 Access the Latest Information www.riausa.net Looking for new products? Want to check product availability? Have a requirement for custom synthesis? Need more information or technical assistance? Email : [email protected] Phone: 973-581-1282 1 Pharmaceuticals (API) Abacavir 136470-78-5 Ambroxol 18683-91-5 Abafungin 129639-79-8 Amikacin Sulfate 37517-28-5 Abiraterone 154229-19-3 Aminocaproic Acid 60-32-2 Acamprosate Calcium 77337-73-6 Aminoglutethimide 125-84-8 Acarbose 56180-94-0 Aminophylline 317-34-0 Acecarbromal 77-66-7 Amisulpride 53583-79-2 Aceclofenac 89796-99-6 Amitriptyline 50-48-6 Aceglatone 642-83-1 Amlodipine Besylate 111470-99-6 Aceglutamide 2490-97-3 Amoxapine 14028-44-5 Acemetacin 53164-05-9 Amoxicillin Trihydrate 61336-70-7 Acetazolamide 59-66-5 Amphotericin B 1397-89-3 Acethropan 9002-60-2 Ampicillin Sodium 69-53-4 Acetohexamide 968-81-0 Anagrelide 68475-42-3 Acitazanolast 114607-46-4 Anastrozole 120511-73-1 Acitretin 55079-83-9 Anidulafungin 166663-25-8 Aclarubicin 57576-44-0 Aniracetam 72432-10-1 Aclarubicin Hydrochloride 75443-99-1 Antazoline Hydrochloride 2508-72-7 Acrivastine 87848-99-5 Anthralin (Dithranol) 1143-38-0 Acyclovir 59277-89-3 Apixaban 503612-47-3 Adalimumab 331731-18-1 Aprepitant 170729-80-3 Adapalene 106685-40-9 Arbidol Hydrochloride 131707-23-8 Adefovir 106941-25-7 Argatroban 74863-84-6 Adefovir Dipivoxil 142340-99-6 Aripiprazole 129722-12-9 Adozelesin 110314-48-2 Asparaginase 9015-68-3 Adrogolide 166591-11-3 Atazanavir 198904-31-3 Afimoxifene 68392-35-8 Atenolol 29122-68-7 Afloqualone 56287-74-2 Atomoxetine Hydrochloride 82248-59-7 Agomelatine 138112-76-2 Atorvastatin Calcium 134523-03-8 Albendazole 54965-21-8 Atovaquone 95233-18-4 Alclometasone Dipropionate 66734-13-2 Atracurium Besylate 64228-79-1 Aldosterone 52-39-1 Avanafil 330784-47-9 Aleglitazar 475479-34-6 Avermectin 73989-17-0 Alendronate Sodium 121268-17-5 Azathioprine 446-86-6 Alfacalcidol 41294-56-8 Azelastine 58581-89-8 Alfaprostol 74176-31-1 Azilsartan 147403-03-0 Alfuzosin 81403-80-7 Azithromycin 83905-01-5 Aliskiren Hemifumarate 173334-57-1 Aztreonam 78110-38-0 Alizapride 59338-93-1 Baclofen 1134-47-0 Allopurinol 315-30-0 Barnidipine Hydrochloride 104757-53-1 Allylestrenol 432-60-0 Batimastat 130370-60-4 Alminoprofen 39718-89-3 Benazepril 86541-75-5 Almotriptan 154323-57-6 Bendamustine Hydrochloride 3543-75-7 Aloxiprin 9014-67-9 Benproperine Phosphate 19428-14-9 Alprazolam 28981-97-7 Benserazide Hydrochloride 14919-77-8 Alprostadil 745-65-3 Benzatropine 86-13-5 Alteplase 105857-23-6 Benzetimide 119391-55-8 Altrenogest 850-52-2 Benzimidavir 176161-24-3 Altretamine 645-05-6 Benzocaine 94-09-7 Alvimopan 156053-89-3 Benzonatate 104-31-4 Amantadine Sulfate 31377-23-8 Benztropine Mesylate 132-17-2 2 Betahistine DiHydrochloride 5579-84-0 Caspofungin Acetate 179463-17-3 Betamethasone Acetate 378-44-9 Cefaclor 53994-73-3 Betamethasone Dipropionate 5593-20-4 Cefdinir 91832-40-5 Betamethasone Sodium Phosphate 151-73-5 Cefepime 88040-23-7 Betamethasone Valerate 2152-44-5 Cefixime 79350-37-1 Betaxolol 63659-18-7 Cefodizime 69739-16-8 Bethanechol Chloride 590-63-6 Cefsulodin Sodium 52152-93-9 Bezafibrate 41859-67-0 Cefuroxime Axetil 64544-07-6 Biapenem 120410-24-4 Celecoxib 169590-42-5 Bicalutamide 90357-06-5 Cetilistat 282526-98-1 Bifonazole 60628-96-8 Cetrizine Dihcl 83881-51-0 Bimatoprost 155206-00-1 Chlorambucil 305-03-3 Bisacodyl 603-50-9 Chloramphenicol Sodium Succinate 56-75-7 Bisoprolol Hemifumarate 104344-23-2 Chloroquine Phosphate 54-05-7 Bivalirudin 128270-60-0 Chlorpheniramine Maleate 113-92-8 Bleomycin Sulfate 11056-06-7 Chlorpromazine Hydrochloride 69-09-0 Boceprevir 394730-60-0 Choline Bitartarate 62-49-7 Boldenone 846-48-0 Ciclopirox 29342-05-0 Boldenone Undecylenate 13103-34-9 Cilostazol 73963-72-1 Bortezomib 179324-69-7 Cimetidine A 51481-61-9 Bosentan 147536-97-8 Cinchocaine (Dibucaine Hydrochloride) 61-12-1 Bosutinib 380843-75-4 Cinnarizine 298-57-7 Brimonidine 59803-98-4 Ciprofibrate 52214-84-3 Brimonidine Tartrate 79570-19-7 Ciprofloxacin Hydrochloride 86483-48-9 Brinzolamide 138890-62-7 Cisapride 81098-60-4 Bromhexine Hydrochloride 611-75-6 Cisatracurium Besylate 96946-42-8 Bromocriptine Mesylate 25614-03-3 Cisplatin 15663-27-1 Budesonide 51333-22-3 Citalopram Hydrobromide 59729-32-7 Budipine 57982-78-2 Clarithromycin 81103-11-9 Bufexamac 2438-72-4 Clenbuterol Hydrochloride 21898-19-1 Buflomedil 55837-25-7 Clindamycin Hydrochloride 21462-39-5 Buformin Hydrochloride 692-13-7 Clindamycin Phosphate 24729-96-2 Bunazosin 80755-51-7 Clinofibrate 30299-08-2 Bupivacaine Hydrochloride 18010-40-7 Clioquinol 130-26-7 Buprenorphine 52485-79-7 Clobetasol 17-Propionate 25122-46-8 Buprenorphine Hydrochloride 53152-21-9 Clomipramine Hydrochloride 17321-77-6 Buspirone 36505-84-7 Clonazepam 1622-61-3 Butenafine Hydrochloride 101827-46-7 Clonidine Hydrochloride 4205-90-7 Butoconazole 64872-76-0 Clonixin Lysinate 17737-65-4 Butorphanol Tartrate 58786-99-5 Clopidogrel Bisulfate 144077-07-6 Cabazitaxel 183133-96-2 Clostebol Acetate 855-19-6 Cabergoline 81409-90-7 Clotrimazole 23593-75-1 Calcipotriol 112965-21-6 Cyclobenzaprine Hydrochloride 6202 23 9 Calcitriol 32222-06-3 Cyclosporine 59865-13-3 Camostat Mesylate 59721-28-7 Dabigatran Etexilate 211915-06-9 Candesartan Cilexetil 139481-59-7 Dactinomycin 50-76-0 Cantharidin 56-25-7 Danazol 17230-88-5 Captopril 62571-86-2 Carbidopa 28860-95-9 Carbamazepine 298-46-4 Carprofen 53716-49-7 Carbazochrome Salicylate 13051-01-9 Carvedilol 72956-09-3 Carbidopa 28860-95-9 Dantrolene Sodium 14663-23-1 Carprofen 53716-49-7 Dapiprazole 72822-12-9 Carvedilol 72956-09-3 Daptomycin 103060-53-3 3 Darunavir 206361-99-1 Dithiazanine Iodide 514-73-8 Dasatinib 302962-49-8 Ditiocarb Sodium 148-18-5 Daunorubicin Hydrochloride 23541-50-6 Docosanol 661-19-8 Deferasirox 201530-41-8 Docusate Sodium 577-11-7 Deferiprone 30652-11-0 Dofetilide 115256-11-6 Deferoxamine Mesilate 138-14-7 Domperidone 57808-66-9 Dehydrocholic Acid 81-23-2 Donepezil Hydrochloride 120011-70-3 Dehydroepiandrosterone (DHEA) 53-43-0 Doramectin 117704-25-3 Delapril Hydrochloride 83435-67-0 Doripenem 148016-81-3 Delavirdine Mesylate 147221-93-0 Dorzolamide Hydrochloride 130693-82-2 Demeclocycline Hydrochloride 64-73-3 Dotarizine 84625-59-2 Desloratadine 100643-71-8 Dovitinib 804551-71-1 Deslorelin Acetate 57773-65-5 Doxapram 309-29-5 Desmopressin Acetate 16679-58-6 Doxazosin Mesylate 74191-85-8 Desonide 638-94-8 Doxepin Hydrochloride 1229-29-4 Desoxycortone Pivalate 808-48-0 Doxercalciferol 54573-75-0 Desvenlafaxine 93413-62-8 Doxofylline 69975-86-6 Detomidine 76631-46-4 Doxorubicin Hydrochloride 25316-40-9 Dexamethasone 50-02-2 Doxycycline Hydrochloride 10592-13-9 Dexchlorpheniramine Maleate 2438 32 6 Droloxifene Citrate 97752-20-0 Dexelvucitabine 134379-77-4 Dropropizine 17692-31-8 Dexetimide 21888-98-2 Drospirenone 67392-87-4 Dexfenfluramine Hydrochloride 3239-45-0 Duloxetine Hydrochloride 136434-34-9 Dexketoprofen Trometamol 156604-79-4 Dutasteride 164656-23-9 Dexmethylphenidate Hydrochloride 19262-68-1 Dyclonine Hydrochloride 536-43-6 Dexrazoxane 24584-09-6 Dydrogesterone 152-62-5 Dextromethorphan Hydrobromide 6700-34-1 Ebastine 90729-43-4 Dextrose Anhydrous 50-99-7 Econazole Nitrate 27220-47-9 Dextrothyroxine Sodium 137-53-1 Edaravone 89-25-8 Dezinamide 91077-32-6 Edatrexate 80576-83-6 Diacerein 13739-02-1 Edoxaban 912273-65-5 Diclazuril 101831-37-2 Edoxudine 15176-29-1 Diclofenac Sodium 15307-86-5 Efavirenz 154598-52-4 Dicloxacillin Sodium 3116-76-5 Eflornithine Hydrochloride 68278-23-9 Dicoumarol 66-76-2 Elacridar 143664-11-3 Didanosine 69655-05-6 Elcatonin 60731-46-6 Diethazine 60-91-3 Eletriptan Hydrobromide 177834-92-3 Diflorasone Diacetate 33564-31-7 Elliptinium Acetate 58337-35-2 Difloxacin 98106-17-3 Elocalcitol 199798-84-0 Diflunisal 22494-42-4 Elsibucol 216167-95-2 Digitoxin 71-63-6 Elvucitabine 181785-84-2 Digoxin 20830-75-5 Emedastine 87233-61-2 Dihydroergotamine Mesylate 511-12-6 Emitefur 110690-43-2 Dilevalol 75659-07-3 Emivirine 149950-60-7 Diloxanide Furoate 3736-81-0 Enalapril 75847-73-3 Diltiazem Hydrochloride 42399-41-7 Eniluracil 59989-18-3 Dimethindene Maleate 3614-69-5 Enocitabine 55726-47-1 Dimetotiazine 7456-24-8 Enprostil 73121-56-9 Dinoprost 551-11-1 Enrofloxacin 93106-60-6 Dinoprostone 363-24-6 Entacapone 130929-57-6 Diphenadione Sodium 42721-99-3 Entecavir 209216-23-9 Dipyridamole 58-32-2 Eperisone 64840-90-0 Disulfiram 97-77-8 Epervudine 134785-30-1 4 Epinastine Hydrochloride 108929-04-0 Flecainide 54143-55-4 Epinephrine Bitartrate 51-42-3 Flomoxef 99665-00-6 Epirubicin Hydrochloride 56390-09-1 Flomoxef Sodium 96647-03-9 Eplerenone 107724-20-9 Floxuridine 50-91-9 Eprinomectin 123997-26-2 Fluanisone 1480-19-9 Epristeride 119169-78-7 Flubendazole 31430-15-6 Eprosartan 133040-01-4 Flucloxacillin Sodium 5250-39-5 Eprosartan Mesylate 144143-96-4 Fluconazole 86386-73-4 Eptaplatin 146665-77-2 Fludarabine 21679-14-1 Erdosteine 84611-23-4 Fludrocortisone Acetate 127-31-1 Ergometrine Maleate 129-51-1 Flufenamic Acid 530-78-9 Ergotamine Tartrate 379-79-3 Flumedroxone Acetate 987-18-8 Erlotinib 183321-74-6 Flumethasone 2135-17-3 Ertapenem 153832-46-3 Flumethasone Pivalate 2002-29-1 Ertapenem Sodium 153773-82-1 Flunarizine 52468-60-7 Erythromycin Phosphate 114-07-8 Flunixin 38677-85-9 Erythropoietin 11096-26-7 Fluocinonide 356-12-7 Esomeprazole Magnesium Trihydrate 217087-09-7 Fluorometholone 426-13-1 Estramustine Sodium Phosphate 52205-73-9 Fluorouracil 51-21-8 Estriol 50-27-1
Load more

Recommended publications
  • Specifications of Approved Drug Compound Library
    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
    [Show full text]
  • Design Novel Dual Agonists for Treating Type-2 Diabetes by Targeting Peroxisome Proliferator-Activated Receptors with Core Hopping Approach
    Design Novel Dual Agonists for Treating Type-2 Diabetes by Targeting Peroxisome Proliferator-Activated Receptors with Core Hopping Approach Ying Ma1., Shu-Qing Wang1,3*., Wei-Ren Xu2, Run-Ling Wang1*, Kuo-Chen Chou3 1 Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, China, 2 Tianjin Institute of Pharmaceutical Research (TIPR), Tianjin, China, 3 Gordon Life Science Institute, San Diego, California, United States of America Abstract Owing to their unique functions in regulating glucose, lipid and cholesterol metabolism, PPARs (peroxisome proliferator- activated receptors) have drawn special attention for developing drugs to treat type-2 diabetes. By combining the lipid benefit of PPAR-alpha agonists (such as fibrates) with the glycemic advantages of the PPAR-gamma agonists (such as thiazolidinediones), the dual PPAR agonists approach can both improve the metabolic effects and minimize the side effects caused by either agent alone, and hence has become a promising strategy for designing effective drugs against type-2 diabetes. In this study, by means of the powerful ‘‘core hopping’’ and ‘‘glide docking’’ techniques, a novel class of PPAR dual agonists was discovered based on the compound GW409544, a well-known dual agonist for both PPAR-alpha and PPAR- gamma modified from the farglitazar structure. It was observed by molecular dynamics simulations that these novel agonists not only possessed the same function as GW409544 did in activating PPAR-alpha and PPAR-gamma, but also had more favorable conformation for binding to the two receptors. It was further validated by the outcomes of their ADME (absorption, distribution, metabolism, and excretion) predictions that the new agonists hold high potential to become drug candidates.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Next-Generation Sequencing Identification and Characterization
    Next-generation sequencing identification and characterization of microsatellite markers in Aconitum austrokoreense Koidz., an endemic and endangered medicinal plant of Korea Y.-E. Yun, J.-N. Yu, G.H. Nam, S.-A. Ryu, S. Kim, K. Oh and C.E. Lim National Institute of Biological Resources, Environmental Research Complex, Incheon, Korea Corresponding author: C.E. Lim E-mail: [email protected] Genet. Mol. Res. 14 (2): 4812-4817 (2015) Received June 11, 2014 Accepted October 29, 2014 Published May 11, 2015 DOI http://dx.doi.org/10.4238/2015.May.11.13 ABSTRACT. We used next-generation sequencing to develop 9 novel microsatellite markers in Aconitum austrokoreense, an endemic and endangered medicinal plant in Korea. Owing to its very limited distribution, over-harvesting for traditional medicinal purposes, and habitat loss, the natural populations are dramatically declining in Korea. All novel microsatellite markers were successfully genotyped using 64 samples from two populations (Mt. Choejeong, Gyeongsangbuk- do and Ungseokbong, Gyeongsangnam-do) of Gyeongsang Province. The number of alleles ranged from 2 to 7 per locus in each population. Observed and expected heterozygosities ranged from 0.031 to 0.938 and from 0.031 to 0.697, respectively. The novel markers will be valuable tools for assessing the genetic diversity of A. austrokoreense and for germplasm conservation of this endangered species. Key words: Aconitum austrokoreense; Microsatellite marker; Endemic and endangered medicinal plant, Next-generation sequencing; Genetic diversity Genetics and Molecular Research 14 (2): 4812-4817 (2015) ©FUNPEC-RP www.funpecrp.com.br Novel microsatellite markers in A. austrokoreense 4813 INTRODUCTION Aconitum austrokoreense Koidz.
    [Show full text]
  • Us 2018 / 0296525 A1
    UN US 20180296525A1 ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2018/ 0296525 A1 ROIZMAN et al. ( 43 ) Pub . Date: Oct. 18 , 2018 ( 54 ) TREATMENT OF AGE - RELATED MACULAR A61K 38 /1709 ( 2013 .01 ) ; A61K 38 / 1866 DEGENERATION AND OTHER EYE (2013 . 01 ) ; A61K 31/ 40 ( 2013 .01 ) DISEASES WITH ONE OR MORE THERAPEUTIC AGENTS (71 ) Applicant: MacRegen , Inc ., San Jose , CA (US ) (57 ) ABSTRACT ( 72 ) Inventors : Keith ROIZMAN , San Jose , CA (US ) ; The present disclosure provides therapeutic agents for the Martin RUDOLF , Luebeck (DE ) treatment of age - related macular degeneration ( AMD ) and other eye disorders. One or more therapeutic agents can be (21 ) Appl. No .: 15 /910 , 992 used to treat any stages ( including the early , intermediate ( 22 ) Filed : Mar. 2 , 2018 and advance stages ) of AMD , and any phenotypes of AMD , including geographic atrophy ( including non -central GA and Related U . S . Application Data central GA ) and neovascularization ( including types 1 , 2 and 3 NV ) . In certain embodiments , an anti - dyslipidemic agent ( 60 ) Provisional application No . 62/ 467 ,073 , filed on Mar . ( e . g . , an apolipoprotein mimetic and / or a statin ) is used 3 , 2017 . alone to treat or slow the progression of atrophic AMD Publication Classification ( including early AMD and intermediate AMD ) , and / or to (51 ) Int. CI. prevent or delay the onset of AMD , advanced AMD and /or A61K 31/ 366 ( 2006 . 01 ) neovascular AMD . In further embodiments , two or more A61P 27 /02 ( 2006 .01 ) therapeutic agents ( e . g ., any combinations of an anti - dys A61K 9 / 00 ( 2006 . 01 ) lipidemic agent, an antioxidant, an anti- inflammatory agent, A61K 31 / 40 ( 2006 .01 ) a complement inhibitor, a neuroprotector and an anti - angio A61K 45 / 06 ( 2006 .01 ) genic agent ) that target multiple underlying factors of AMD A61K 38 / 17 ( 2006 .01 ) ( e .
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,314.465 B2 Brew Et Al
    US009314465B2 (12) United States Patent (10) Patent No.: US 9,314.465 B2 Brew et al. (45) Date of Patent: *Apr. 19, 2016 (54) DRUG COMBINATIONS AND USES IN 2008.0003280 A1 1/2008 Levine et al. ................. 424/456 TREATING A COUGHING CONDITION 2008/O176955 A1 7/2008 Hecket al. 2008, 0220078 A1 9, 2008 Morton et al. (71) Applicant: Infirst Healthcare Limited 2009, O136427 A1 5/2009 Croft et al. 2009, O220594 A1 9, 2009 Field (72) Inventors: John Brew, London (GB); Robin Mark 2012/O128738 A1 5, 2012 Brew et al. Bannister, London (GB) 2012fO252824 A1 10/2012 Brew et al. (73) Assignee: Infirst Healthcare Limited, London FOREIGN PATENT DOCUMENTS (GB) CN 1593451 3, 2005 CN 101024.014 A 8, 2007 (*) Notice: Subject to any disclaimer, the term of this CN 101112383 B 5, 2010 patent is extended or adjusted under 35 DE 4420708 A1 12, 1995 U.S.C. 154(b) by 0 days. EP 2050435 B1 4/2009 GB 2114001 A 8, 1983 This patent is Subject to a terminal dis GB 2284761 A 6, 1995 claimer. GB 2424.185 B 9, 2006 GB 2442828 A 4/2008 JP 62-249924 A 10, 1987 (21) Appl. No.: 14/287,014 JP H1O-316568 A 12/1998 JP 2001-518928 A 10, 2001 (22) Filed: May 24, 2014 JP 200219.3839. A T 2002 JP 2003-012514 A 1, 2003 (65) Prior Publication Data JP 20030552.58 A 2, 2003 JP 2003128549 A 5, 2003 US 2014/O256750 A1 Sep. 11, 2014 JP 2003-321357 A 11, 2003 JP 2005-516917 A 6, 2005 JP 2008O31146 A 2, 2008 Related U.S.
    [Show full text]
  • ACCP Guideline: Diagnosis and Management of Cough
    Diagnosis and Management of Cough Executive Summary ACCP Evidence-Based Clinical Practice Guidelines Richard S. Irwin, MD, FCCP, Chair; Michael H. Baumann, MD, FCCP (HSP Liaison); Donald C. Bolser, PhD; Louis-Philippe Boulet, MD, FCCP (CTS Representative); Sidney S. Braman, MD, FCCP; Christopher E. Brightling, MBBS, FCCP; Kevin K. Brown, MD, FCCP; Brendan J. Canning, PhD; Anne B. Chang, MBBS, PhD; Peter V. Dicpinigaitis, MD, FCCP; Ron Eccles, DSc; W. Brendle Glomb, MD, FCCP; Larry B. Goldstein, MD; LeRoy M. Graham, MD, FCCP; Frederick E. Hargreave, MD; Paul A. Kvale, MD, FCCP; Sandra Zelman Lewis, PhD; F. Dennis McCool, MD, FCCP; Douglas C. McCrory, MD, MHSc; Udaya B.S. Prakash, MD, FCCP; Melvin R. Pratter, MD, FCCP; Mark J. Rosen, MD, FCCP; Edward Schulman, MD, FCCP (ATS Representative); John Jay Shannon, MD, FCCP (ACP Representative); Carol Smith Hammond, PhD; and Susan M. Tarlo, MBBS, FCCP (CHEST 2006; 129:1S–23S) Abbreviations: ACE ϭ angiotensin-converting enzyme; ACP ϭ American College of Physicians; A/D ϭ antihistamine/ decongestant; ATS ϭ American Thoracic Society; BPC ϭ bronchoprovocation challenge; CTS ϭ Canadian Thoracic Society; DPB ϭ diffuse panbronchiolitis; dTap ϭ acellular pertussis; FEES ϭ fiberoptic endoscopic evaluation of swallowing; GERD ϭ gastroesophageal reflux disease; HRCT ϭ high-resolution CT; HSP ϭ Health & Psychosocial Instruments; IBD ϭ inflammatory bowel disease; ICS ϭ inhaled corticosteroid; ILD ϭ interstitial lung disease; NAEB ϭ nonasthmatic eosinophilic bronchitis; NSCLC ϭ non-small cell lung cancer; SLP ϭ speech-language pathol- ogist; TB ϭ tuberculosis; UACS ϭ upper airway cough syndrome; URI ϭ upper respiratory infection; VC ϭ voluntary cough; VSE ϭ videofluoroscopic swallow evaluation ecognition of the importance of cough in clinical (3) updates and expands, when appropriate, all pre- R medicine was the impetus for the original evi- vious sections; and (4) adds new sections with topics dence-based consensus panel report on “Managing that were not previously covered.
    [Show full text]
  • The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development
    International Journal of Molecular Sciences Review The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development Fan Hong 1,2, Pengfei Xu 1,*,† and Yonggong Zhai 1,2,* 1 Beijing Key Laboratory of Gene Resource and Molecular Development, College of Life Sciences, Beijing Normal University, Beijing 100875, China; [email protected] 2 Key Laboratory for Cell Proliferation and Regulation Biology of State Education Ministry, College of Life Sciences, Beijing Normal University, Beijing 100875, China * Correspondence: [email protected] (P.X.); [email protected] (Y.Z.); Tel.: +86-156-005-60991 (P.X.); +86-10-5880-6656 (Y.Z.) † Current address: Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15213, USA. Received: 22 June 2018; Accepted: 24 July 2018; Published: 27 July 2018 Abstract: Peroxisome proliferator-activated receptors (PPARs) are a well-known pharmacological target for the treatment of multiple diseases, including diabetes mellitus, dyslipidemia, cardiovascular diseases and even primary biliary cholangitis, gout, cancer, Alzheimer’s disease and ulcerative colitis. The three PPAR isoforms (α, β/δ and γ) have emerged as integrators of glucose and lipid metabolic signaling networks. Typically, PPARα is activated by fibrates, which are commonly used therapeutic agents in the treatment of dyslipidemia. The pharmacological activators of PPARγ include thiazolidinediones (TZDs), which are insulin sensitizers used in the treatment of type 2 diabetes mellitus (T2DM), despite some drawbacks. In this review, we summarize 84 types of PPAR synthetic ligands introduced to date for the treatment of metabolic and other diseases and provide a comprehensive analysis of the current applications and problems of these ligands in clinical drug discovery and development.
    [Show full text]
  • Research Article to Probe Full and Partial Activation
    Hindawi PPAR Research Volume 2020, Article ID 5314187, 24 pages https://doi.org/10.1155/2020/5314187 Research Article To Probe Full and Partial Activation of Human Peroxisome Proliferator-Activated Receptors by Pan-Agonist Chiglitazar Using Molecular Dynamics Simulations Holli-Joi Sullivan,1 Xiaoyan Wang,2,3 Shaina Nogle,1 Siyan Liao,1,4 and Chun Wu 1 1College of Science and Mathematics, Rowan University, Glassboro, NJ 08028, USA 2School of Radiology, Taishan Medical University, Tai’an, Shandong 271016, China 3Medical School, Southeast University, Nanjing 210009, China 4Key Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou 511436, China Correspondence should be addressed to Chun Wu; [email protected] Received 13 January 2020; Revised 25 February 2020; Accepted 3 March 2020; Published 1 April 2020 Academic Editor: Tom Hsun-Wei Huang Copyright © 2020 Holli-Joi Sullivan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Chiglitazar is a promising new-generation insulin sensitizer with low reverse effects for the treatment of type II diabetes mellitus (T2DM) and has shown activity as a nonselective pan-agonist to the human peroxisome proliferator-activated receptors (PPARs) (i.e., full activation of PPARγ and a partial activation of PPARα and PPARβ/δ). Yet, it has no high-resolution complex structure with PPARs and its detailed interactions and activation mechanism remain unclear. In this study, we docked chiglitazar into three experimentally resolved crystal structures of hPPAR subtypes, PPARα, PPARβ/δ, and PPARγ, followed by 3 μs molecular dynamics simulations for each system.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • General Pharmacology
    GENERAL PHARMACOLOGY Winners of “Nobel” prize for their contribution to pharmacology Year Name Contribution 1923 Frederick Banting Discovery of insulin John McLeod 1939 Gerhard Domagk Discovery of antibacterial effects of prontosil 1945 Sir Alexander Fleming Discovery of penicillin & its purification Ernst Boris Chain Sir Howard Walter Florey 1952 Selman Abraham Waksman Discovery of streptomycin 1982 Sir John R.Vane Discovery of prostaglandins 1999 Alfred G.Gilman Discovery of G proteins & their role in signal transduction in cells Martin Rodbell 1999 Arvid Carlson Discovery that dopamine is neurotransmitter in the brain whose depletion leads to symptoms of Parkinson’s disease Drug nomenclature: i. Chemical name ii. Non-proprietary name iii. Proprietary (Brand) name Source of drugs: Natural – plant /animal derivatives Synthetic/semisynthetic Plant Part Drug obtained Pilocarpus microphyllus Leaflets Pilocarpine Atropa belladonna Atropine Datura stramonium Physostigma venenosum dried, ripe seed Physostigmine Ephedra vulgaris Ephedrine Digitalis lanata Digoxin Strychnos toxifera Curare group of drugs Chondrodendron tomentosum Cannabis indica (Marijuana) Various parts are used ∆9Tetrahydrocannabinol (THC) Bhang - the dried leaves Ganja - the dried female inflorescence Charas- is the dried resinous extract from the flowering tops & leaves Papaver somniferum, P album Poppy seed pod/ Capsule Natural opiates such as morphine, codeine, thebaine Cinchona bark Quinine Vinca rosea periwinkle plant Vinca alkaloids Podophyllum peltatum the mayapple
    [Show full text]
  • Mucoactive Agents for Airway Mucus Hypersecretory Diseases
    Mucoactive Agents for Airway Mucus Hypersecretory Diseases Duncan F Rogers PhD FIBiol Introduction Sputum Profile of Airway Inflammation and Mucus Hypersecretory Phenotype in Asthma, COPD, and CF Which Aspect of Airway Mucus Hypersecretion to Target? Theoretical Requirements for Effective Therapy of Airway Mucus Hypersecretion Current Recommendations for Clinical Use of Mucolytic Drugs Mucoactive Drugs N-Acetylcysteine: How Does it Work? Does it Work? Dornase Alfa Hypertonic Saline Surfactant Analysis Summary Airway mucus hypersecretion is a feature of a number of severe respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis (CF). However, each disease has a different airway inflammatory response, with consequent, and presumably linked, mucus hypersecretory phenotype. Thus, it is possible that optimal treatment of the mucus hyper- secretory element of each disease should be disease-specific. Nevertheless, mucoactive drugs are a longstanding and popular therapeutic option, and numerous compounds (eg, N-acetylcysteine, erdosteine, and ambroxol) are available for clinical use worldwide. However, rational recommen- dation of these drugs in guidelines for management of asthma, COPD, or CF has been hampered by lack of information from well-designed clinical trials. In addition, the mechanism of action of most of these drugs is unknown. Consequently, although it is possible to categorize them according to putative mechanisms of action, as expectorants (aid and/or induce cough), mucolytics (thin
    [Show full text]